This bill amends Chapter 17, Title 54 of the Idaho Code by adding a new section, 54-1740, which establishes regulations regarding the actions of pharmaceutical manufacturers in relation to the 340B drug pricing program. The new provisions prohibit pharmaceutical manufacturers from denying or interfering with the acquisition and delivery of 340B drugs to contract pharmacies on behalf of covered entities. Additionally, manufacturers are barred from restricting pharmacy contracts between covered entities and contract pharmacies, as well as from requiring any claims or data submissions as a condition for drug acquisition, except for specific compliance audits.

The bill also clarifies that its provisions are intended to be consistent with federal law and that if the federal 340B drug pricing program is eliminated, the state provisions will become null and void. The act is declared to be an emergency measure and is set to take effect on July 1, 2025.